We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Coagulation and Fibrinolysis Assessed in Splenic Injury Patients

By LabMedica International staff writers
Posted on 19 May 2021
Image: The Star Evolution coagulation analyzer (Photo courtesy of Diagnostica Stago)
Image: The Star Evolution coagulation analyzer (Photo courtesy of Diagnostica Stago)
The most frequently injured solid organ following blunt abdominal trauma is the spleen. Splenectomy was a standard surgical procedure for splenic injury until the mid‐20th century. However, thrombotic and infectious complications following splenectomy were demonstrated by many studies.

Thrombocytosis, alterations of coagulation and fibrinolysis contribute to hypercoagulability and thromboembolism. Platelet (PLT) count, fibrinogen (FIB), D‐dimers (D‐D), fibrinogen/fibrin degradation products (FDP), antithrombin III (AT III) are key markers of coagulation and fibrinolytic activity. Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) are used for routine coagulation testing.

Emergency Medicine Specialist at the University of Science and Technology of China (Hefei, China) included in a study 38 blunt splenic injury (BSI). Splenic artery embolization (SAE) was performed if the splenic injury was classed as grade III or greater and had no requirement of immediate surgery.

Blood samples were collected in tubes containing EDTA for PLT count and Hb, hematocrit (Hct) determinations, which were determined using Sysmex XE‐5000 automated hematology analyzer (Sysmex, Kobe, Japan). Samples were collected in tubes containing 3.2% sodium citrate and then centrifuged at 2,000 rpm for 20 minutes to obtain plasma, which was used for determining coagulation and fibrinolysis parameters. FIB, D‐D, FDP, AT III, PT, APTT, and TT were measured on the STA‐R Evolution automated coagulation analyzer with identical commercial kit (Diagnostica Stago, Asnieres, France).

The medical team reported that the technical success rate of SAE and the splenic salvage rate were 100%. There was no mortality. Compared with pre‐SAE values, the levels of PLT, FIB, D‐D, and FDP increased significantly at three days and seven days after SAE. However, AT III, PT, APTT, TT, Hb, and Hct showed no statistically significant difference at one day, three days, and seven days after SAE.

The authors concluded that they had demonstrated that PLT significantly increased and activation of coagulation and fibrinolysis took place in BSI patients undergoing SAE. These alterations might have contributed to the increased risk of thrombotic complications, especially three days and seven days after SAE. Despite SAE as a critical treatment is used extensively in BSI patients and has increased the success rate of NOM, thromboembolism following SAE should be considered and thrombotic prophylaxis should be recommended. The study was published on May 6, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Science and Technology of China
Sysmex
Diagnostica Stago


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more